Microsoft Incident Response – Detection and Response Team (DART) researchers uncovered a new backdoor that is notable for its novel use of the OpenAI Assistants Application Programming Interface (API) ...
Two years after revamping its developer programs and pricing, X is expanding the closed beta of a pay-per-use plan for its ...
STUDI KASUS PPG - Grafis tentang contoh studi kasus PPG 2025 sebanyak 500 kata yang dibuat di aplikasi Canva Premium, Selasa (29/7/2025). Simak contoh studi kasus PPG 2025 saat UKPPPG tentang masalah ...
4 Contoh Jurnal Modul 3 Filosofi Pendidikan dan Pendidikan Nilai PPG 2025 Topik 1,2 dan 3 Divalidasi
JURNAL MODUL 3 - Desain grafis contoh Jurnal Modul 3 Filosofi Pendidikan dan Pendidikan Nilai (FPPN) lengkap Topik 1,2,3 PPG dibuat dengan Canva, Jumat (20/6/2025). Inilah 4 contoh Jurnal Modul 3 ...
Shares of Neuphoria Therapeutics were trading in the red in the after-hours session Monday, as the company announced a strategic review following news BNC210 anti-anxiety drug didn't meet the primary ...
KOMPAS.com - Komponen komputer kiranya menjadi pengetahuan dasar yang perlu dipahami pengguna jika ingin belajar mengoperasikannya. Komputer adalah perangkat elektronik yang berfungsi untuk memproses, ...
OpenAI unveiled new API updates at its Dev Day on Monday, introducing GPT-5 Pro, its latest language model, its new video generation model Sora 2, and a smaller, cheaper voice model. The addition of ...
Microsoft is working to resolve a known issue that causes its Defender for Endpoint enterprise endpoint security platform to incorrectly tag SQL Server software as end-of-life. According to a service ...
Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test
Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer. The biopharma evaluated the Bristol Myers Squibb-partnered ...
ONO-4578, an EP4 antagonist, in combination with Opdivo and chemotherapy demonstrated a significant prolongation of progression-free survival compared with placebo in combination with Opdivo and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results